David-Alexandre "DA" Gros

Chief Executive Officer & Director at Eledon Pharmaceuticals
Summary
David-Alexandre Gros is an accomplished professional with a diverse background in both the fields of business and medicine.
He holds an MBA from Harvard Business School, an MD from The Johns Hopkins University School of Medicine, and an AB from Dartmouth College.
Currently, David-Alexandre Gros serves as the Chief Executive Officer and Director at Eledon Pharmaceuticals, Inc., showcasing his leadership and management skills.
His past experiences include roles such as Senior Advisor at Pardes Biosciences, Co-Founder of Eliem Therapeutics, and President and Chief Operating Officer at Neurocrine Biosciences, which reflect his expertise in the pharmaceutical industry.
David-Alexandre Gros has also been involved in strategic positions such as Chief Strategy Officer at Sanofi and Associate Principal at McKinsey & Co., demonstrating his business acumen and analytical capabilities.
With a background in healthcare investment banking at prestigious firms like Merrill Lynch and Centerview Partners, he brings a unique blend of medical knowledge and financial expertise to his professional endeavors.
David-Alexandre Gros's vast experience includes serving on multiple boards, including as a Member of the Corporate Strategy Advisory Board at 4D Molecular Therapeutics and as a Member of the Board of Directors at Saint Jean.
He has also ventured into entrepreneurial roles, having been a Co-Founder at companies like Imbria Pharmaceuticals and Eliem Therapeutics, highlighting his innovative spirit and entrepreneurial drive.
Having worked across various sectors within the healthcare and pharmaceutical industries, David-Alexandre Gros brings a wealth of knowledge and a well-rounded perspective to his current role at Eledon Pharmaceuticals, Inc.